Corpus ID: 12529216

[Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy].

  title={[Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy].},
  author={M. Waragai and K. Ogawara and Y. Takaya and M. Hayashi},
  journal={Rinsho shinkeigaku = Clinical neurology},
  volume={37 7},
Thyrotropin releasing hormone (TRH) therapy has been frequently attempted for the treatment of spinocerebellar degeneration (SCD) and its efficacy has been confirmed. However, effectiveness is considered to differ depending on disease type, severity and the method of evaluating clinical improvement. We investigated the efficacy of thyrotropin releasing hormone-tartrate (TRH-T) in 23 patients with SCD consisting of cerebellar form (cortical cerebellar atrophy (CCA) and hereditary cortical… Expand
Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT
Findings indicate that TRH therapy may increase cerebellar rCBF in some patients with Cerebellar forms of SCD and that 3DSRT may be useful for evaluating the efficacy of TRH for increasing CBF. Expand
Treatment of cerebellar ataxia with 5-HT1A agonist
The few published clinical trials that involved the use of 5-HT 1A receptor agonists for the treatment of cerebellar ataxia were reviewed, and the current theories regarding their mechanism of action were discussed. Expand
Evaluation of the Effects of Thyrotropin Releasing Hormone (TRH) Therapy on Regional Cerebral Blood Flow in the Cerebellar Variant of Multiple System Atrophy Using 3DSRT
Thyrotropin releasing hormone (TRH) improves cerebellar ataxia and cerebellar perfusion in patients with spinocerebellar degeneration. It is not known whether TRH therapy can improve the cerebellarExpand
Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial.
It is concluded that BCAAs do have a beneficial effect on functional improvement in patients with SCD, and that further large scale studies are needed. Expand
Spinocerebellar degeneration
The spinocerebellar degenerations/ataxias (SCAs) are a diverse group of rare, slowly progressive, neurological diseases, often inherited but of incompletely understood pathophysiology, which affectExpand
Subclinical rhythmic electrographic discharge of adults (SREDA) in a case with spinocerebellar degeneration improved clinically by thyrotropin‐releasing hormone
Herein, we report on a patient with spinocerebellar degeneration who exhibited subclinical rhythmic electrographic discharge of adults (SREDA). Thyrotropin‐releasing hormone (TRH) improved theExpand
Symptomatic and Disease-Modifying Therapy for the Progressive Ataxias
There are as yet no drugs that have been approved by the Food and Drug Administration for the treatment of the progressive ataxias and relatively few disease-modifying therapies, but symptomatic and rehabilitation interventions can greatly improve the quality of life of individuals with these disabling neurodegenerative disorders. Expand
Taltirelin (Tanabe Seiyaku).
: Taltirelin is a synthetic thyrotropin-releasing hormone (TRH) analog, under development by Tanabe Seiyaku for the treatment of neurodegenerative diseases. A new drug application (NDA) has beenExpand
Beneficial effects of tandospirone on ataxia of a patient with Machado‐Joseph disease
The first case of a patient with Machado‐Joseph disease in which tandospirone citrate is successfully treated cerebellar ataxia is reported, and his leg pain, insomnia, anorexia, and depression, which are thought to be related to 5‐HT1A receptors, were also remarkably alleviated by treatment with tandosphereirone. Expand
Critical appraisal of clinical trials in multiple system atrophy: Toward better quality
Overall, the design and quality of reporting of the reviewed studies is unsatisfactory and methodological quality and trial design need to be optimized to generate more informative results. Expand